MDLN
Medline Inc.
MDLN has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MDLN overall, supported by stronger fundamentals and stronger modeled upside.
MDLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Healthy | |
| Weak |
MDLN's profitability and cash flow are currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDLN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 33x | $22.09 | -45% |
| Fair | 40x | $27.00 | -32% |
| Expensive | 42x | $28.23 | -29% |
| Current | 60x | $39.98 | — |
Historical ranges are pointers, not guarantees.
MDLN's PE is 60x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over MDLN in the historical PE scenario, which offers more potential upside but is not a forecast.
MDLN Forward outlook
There aren't enough analyst estimates for MDLN to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MDLN Earnings Per Share
MDLN and OSCR do not have enough comparable growth data to identify a winner.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
MDLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.9B | +10% |
| Q2 2026 | $7.7B | +12% |
| Q1 2026 | $7.4B | +11% |
| Q3 2025 | $7.1B | +11% |
| Q2 2025 | $6.9B | +11% |
MDLN's revenue has grown year over year every quarter since late 2025: $7.9B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.4% | -1.7 points |
| Q2 2026 | 5.1% | -4 points |
| Q1 2026 | 5.7% | -3.2 points |
| Q4 2025 | 5.5% | N/A |
| Q3 2025 | 8.1% | -0.9 points |
| Q2 2025 | 9.1% | +0.8 points |
| Q1 2025 | 8.9% | N/A |
| Q3 2024 | 9% | N/A |
MDLN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MDLN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MDLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $884M | +65% |
| Q2 2026 | $604M | +486% |
| Q1 2026 | $316M | -41% |
| Q3 2025 | $535M | -13% |
MDLN's free cash flow has been positive every quarter since late 2024: $2.4B over the past year, up 33% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
MDLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +53% | +455M shares |
| 1 year | +67% | +529M shares |
MDLN has 1.3B diluted shares, up 67% from a year ago, despite $2B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $2B |
| Q3 2025 | $18M |
| Q2 2025 | $3M |
| Q1 2025 | $18M |
| Q3 2024 | $3M |
MDLN spent $2B buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over MDLN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MDLN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.0x | High |
| Q2 2026 | 3.9x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.6x | Elevated |
MDLN's net debt is about 4.0 years of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MDLN on leverage, with a lower net debt burden relative to earnings.
MDLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.9 | Neutral |
| Stochastic | 53.6 | Neutral |
MDLN's weekly RSI is 57 (neutral) and its Stochastic is 54 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MDLN PE vs Healthcare Sector
| Metric | MDLN | Sector median | Relative |
|---|---|---|---|
| PE | 60x | 26x | 131% above |
MDLN is trading at 60x earnings, a 131% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MDLN on valuation relative to its sector.
MDLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.1 | 11% above |
| 20 week MA | $36.6 | 9.3% above |
OSCR has stronger trend alignment. MDLN is above 2 of 2 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MDLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $41.7 | $44.1 | +6% |
| 2026 YTD | $44.1 | $40.0 | -9.4% |
MDLN has finished every year since 2025 higher, and it's down 9.4% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MDLN on returns for 2026, with the stronger performance.